Vaccinia Virus Complement Control Protein Diminishes Formation of Atherosclerotic Lesions: Complement Is Centrally Involved in Atherosclerotic Disease
- 1 November 2005
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1056 (1) , 1-15
- https://doi.org/10.1196/annals.1352.001
Abstract
Complement is known to be activated in atherosclerotic lesions, but the importance of this event in disease pathology is a matter of debate. Studies of rabbits fed a high‐fat diet have indicated complement activation as a rate‐limiting step, whereas results from genetically modified mouse strains (ApoE−/− or LDLR−/−) have failed to support this finding. To resolve whether this reflects differences between species or between genetically driven and diet‐induced disease, we studied the effect of a complement inhibitor, vaccinia virus complement control protein (VCP), on C57BL/6 mice, the background strain of ApoE−/− and LDLR−/− mice. Atherosclerosis was induced by a high‐fat diet, and VCP (20 mg/kg) was injected once per week after the eighth week. Fatty streak development was monitored at 15 weeks by microscopic examination of oil red‐O‐stained sections from the root of the aorta. VCP injections led to significant (50%) reduction of lesion size (P= 0.004). Lesions were marked by gradual accumulation of lipids and macrophages but did not develop beyond the fatty streak stage. VCP activity disappeared from serum in 4 days, and the possibility therefore exists that a higher level of protection may be achieved by more frequent injections. We conclude that the development of fatty streaks in diet‐induced atherosclerotic disease can be significantly retarded by prophylactic treatment with a complement inhibitor. These results support previous findings from complement‐deficient rabbits and suggest that the pathogenesis of atherosclerosis in diet‐induced disease differs from that induced by major defects in lipid metabolism.Keywords
This publication has 56 references indexed in Scilit:
- An Age‐Associated Decrease in the Frequency of C4B*Q0 Indicates That Null Alleles of Complement May Affect Health or SurvivalAnnals of the New York Academy of Sciences, 2003
- Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activationTransplant Immunology, 2003
- Association Between Complement Factor H and Proteoglycans in Early Human Coronary Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Inflammation in atherosclerosisNature, 2002
- Innate and acquired immunity in atherogenesisNature Medicine, 2002
- ApoE−/− Mice Develop Atherosclerosis in the Absence of Complement Component C5Biochemical and Biophysical Research Communications, 2001
- ComplementNew England Journal of Medicine, 2001
- ComplementNew England Journal of Medicine, 2001
- RETRACTED: Crystal Structure of a Complement Control Protein that Regulates Both Pathways of Complement Activation and Binds Heparan Sulfate ProteoglycansCell, 2001
- CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesionsAtherosclerosis, 1992